



WINDSOR  
REGIONAL  
HOSPITAL

OUTSTANDING CARE – NO EXCEPTIONS!

June 3, 2021

BOARD OF DIRECTOR'S  
MEETING

69 Ward/non critical care transfers from GTA


21 ICU transfers mostly from London - 3 from Manitoba

**Total = 90 transfers accepted both ward/non critical care and ICU patients**

To date 83 discharged - 4 in ICU



# Way Forward



**Stabilize** health system and workforce to ensure available capacity to recover from COVID-19. Lifting temporary and emergency measures in place to manage the urgent capacity needs.

**Restore** functionality in areas where pandemic adversely affected care and services (while addressing pre-existing health inequities, prioritizing populations and communities disproportionately impacted by COVID-19).

**Sustain** positive changes that have been effective.

**Transform** the system to adopt new processes, care pathways, and structures in areas where fundamental change is required.



# New Names for VOC/VOI

## Variants of Concern

A SARS-CoV-2 variant that meets the definition of a VOI (see below) and, through a comparative assessment, has been demonstrated to be associated with one or more of the following changes at a degree of global public health significance:

- Increase in transmissibility or detrimental change in COVID-19 epidemiology; or
- Increase in virulence or change in clinical disease presentation; or
- Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics.

WHO label	Pango lineage	GISAID clade/lineage	Nextstrain clade	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY (formerly GR/501Y.V1)	20I/S:501Y.V1	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351	GH/501Y.V2	20H/S:501Y.V2	South Africa, May-2020	18-Dec-2020
Gamma	P.1	GR/501Y.V3	20J/S:501Y.V3	Brazil, Nov-2020	11-Jan-2021
Delta	B.1.617.2	G/452R.V3	21A/S:478K	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021

## Variants of Interest

A SARS-CoV-2 isolate is a Variant of Interest (VOI) if, compared to a reference isolate, its genome has mutations with established or suspected phenotypic implications, and either:

- has been identified to cause community transmission/multiple COVID-19 cases/clusters, or has been detected in multiple countries; OR
- is otherwise assessed to be a VOI by WHO in consultation with the WHO SARS-CoV-2 Virus Evolution Working Group.

WHO label	Pango lineage	GISAID clade/lineage	Nextstrain clade	Earliest documented samples	Date of designation
Epsilon	B.1.427/B.1.429	GH/452R.V1	20C/S.452R	United States of America, Mar-2020	5-Mar-2021
Zeta	P.2	GR	20B/S.484K	Brazil, Apr-2020	17-Mar-2021
Eta	B.1.525	G/484K.V3	20A/S484K	Multiple countries, Dec-2020	17-Mar-2021
Theta	P.3	GR	20B/S:265C	Philippines, Jan-2021	24-Mar-2021
Iota	B.1.526	GH	20C/S:484K	United States of America, Nov-2020	24-Mar-2021
Kappa	B.1.617.1	G/452R.V3	21A/S:154K	India, Oct-2020	4-Apr-2021




# Vaccination - First Dose

## Share of people who received at least one dose of COVID-19 vaccine, Jun 1, 2021

Our World  
in Data


Share of the total population that received at least one vaccine dose. This may not equal the share that are fully vaccinated if the vaccine requires two doses.

+ Add country




Source: Official data collated by Our World in Data - Last updated 2 June, 11:00 (London OurWorldInData.org/coronavirus • CC BY)

# Vaccination – First Dose



# Second Dose




Source: Official data collated by Our World in Data

CC BY



# Vaccination – First and Second Dose





# Variants – One Dose versus Two Doses

## Vaccines highly effective against B.1.617.2 variant after 2 doses

New study by PHE shows for the first time that 2 doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.

From: [Public Health England](#)  
Published 22 May 2021  
Last updated 22 May 2021 — [See all updates](#)



Vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after 2 doses compared to the B.1.1.7 (Kent) variant dominant in the UK, and we expect to see even higher levels of effectiveness against hospitalisation and death.

The [study found](#) that, for the period from 5 April to 16 May:

- the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93% effectiveness against the B.1.1.7 variant
- 2 doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the B.1.617.2 variant compared to 66% effectiveness against the B.1.1.7 variant
- both vaccines were 33% effective against symptomatic disease from B.1.617.2, 3 weeks after the first dose compared to around 50% effectiveness against the B.1.1.7 variant

HEALTH

## 2nd COVID-19 shots should be offered 'as soon as possible': NACI




By [Twinkle Ghosh](#) • Global News


Posted May 28, 2021 12:43 pm

# Windsor-Essex Vaccination Stats - WECHU

## Vaccination Status of New Cases from December 1 to May 21




## COVID-19 Cases by Vaccination Status: December 1 to May 21





# Windsor-Essex Age Group Vaccination %

## WEC Residents Vaccinated With At Least One Dose by Age Group



2021-05-28



# What could be coming – Border – Testing and Screening Advisory Panel – Recommendations



<https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing-screening-advisory-panel/reports-summaries/priority-strategies-quarantine-borders.html>

Figure 3: Summary of border measure recommendations

BORDER MEASURES FOR PERSONS ENTERING CANADA					
	Non-exempt travellers			Travellers with proof of previous infection	Exempt travellers
	Not vaccinated	Partially <sup>1</sup> vaccinated	Fully vaccinated		
Pre-departure test	✓	✓			
Arrival test	✓	✓	✓	✓	
Quarantine <sup>2</sup> + arrival test with exit after negative arrival test		✓		✓	
Quarantine <sup>2</sup> + day-7 test with exit after negative day-7 test	✓				
Voluntary testing					✓

1. Have received a single dose of a two-dose vaccine, and are within the recommended maximum interval period between doses.  
 2. Travellers who do not undergo an arrival test or day-7 test must quarantine for 14 days.  
 \* "Vaccinated" refers to vaccines authorized in Canada, where 14 days passed since receiving the final dose.



# What could be coming – Border

## U.K. PM Boris Johnson says he wants a deal with G7 on vaccine passports



PM says he wants G7 to sign on to plan to vaccinate entire world by end of 2022

Peter Zimonjic · CBC News · Posted: May 30, 2021 11:00 AM ET | Last Updated: May 30



In an exclusive interview with CBC News chief political correspondent Rosemary Barton, British Prime Minister Boris Johnson says "there has to be some sort of agreement" among G7 countries on COVID-19 vaccine passports to help kickstart international travel when he hosts the G7 Leaders' Summit in the United Kingdom next month. 10:30

2876 comments

British Prime Minister Boris Johnson says he is looking to the G7 to come to an agreement on implementing vaccine passports and to start discussions on a global pandemic preparedness treaty at next month's meeting in the United Kingdom.

"We need to have agreements on issues such as vaccine passports, COVID status certification and the rest," Johnson told CBC News chief political correspondent Rosemary Barton in an exclusive Canadian interview airing today.

"There has to be some sort of agreement then, at the G7 level, to start, on how travel and passports are going to work going forward."

While Prime Minister Justin Trudeau has said that it's too early to discuss reopening the country to international travel, a statement put out by the Prime Minister's Office after Thursday's virtual meeting between the premiers and Trudeau said that discussions on the subject have begun.

"A broad consensus emerged out of the discussion between first ministers on collaborative efforts to develop a proof of vaccine credential to enable international travel based on sound principles, including respect for provincial and territorial jurisdiction and privacy of health information," the statement said.

## G7 Countries



Do you want a digital copy of your COVID-19 vaccination receipt(s) go to <https://covid19.ontariohealth.ca> You will need to log on using your Health Card Pick "Vaccine Receipts"



# What could be coming – Border

NEW: Biden says he'll donate an initial batch of 25 million vaccines.

🇺🇸 19 million will go to Covax, including 6 million to the Americas, 7 million to Asia, 5 million to Africa

🇺🇸 6 million will go to "regional priorities and partner recipients," including Mexico, Korea, others

Approximately 6 million will be targeted toward regional priorities and partner recipients, including Mexico, Canada, and the Republic of Korea, West Bank and Gaza, Ukraine, Kosovo, Haiti, Georgia, Egypt, Jordan, Iraq, and Yemen, as well as for United Nations frontline workers.

Do you want a digital copy of your COVID-19 vaccination receipt(s) go to <https://covid19.ontariohealth.ca> You will need to log on using your Health Card. Pick "Vaccine Receipts"